Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

NCT07591831 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Platinum-resistant Recurrent Ovarian Cancer
Fallopian Tube Cancers
Epithelial Ovarian Cancer
Primary Peritoneal Cancer

Interventions

DRUG: Liposomal Irinotecan

Sponsor

Tianjin Medical University Cancer Institute and Hospital